Clinical Trial Update: A Follow-up Study to Assess Safety and Tolerability of Galantamine Treatment in Individuals With Mild Cognitive Impairment [Phase 3]

View source ↗

Summary

A Phase 3 follow-up study evaluating the safety and tolerability of galantamine in individuals with mild cognitive impairment has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cognitive Impairment

Drugs mentioned

• Galantamine (galantamine)

Snippet

Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Conditions: Cognition Disorder, Nervous System Diseases | Phase 3 | Status: COMPLETED